Novel Cancer Therapy that Simultaneously Treats Primary & Metastatic Tumors

Overview

NorthShore University HealthSystem is seeking a company to license and/or co-develop a potential oncolytic adenovirus cancer therapy that targets both the primary cancer tumor as well as the metastases.  One in three Americans will be diagnosed with cancer in their lifetime, and approximately half a million people die each year.  This invention represents one of the first in a class of oncolytic adenovirus therapies that drastically improves the selectivity and efficacy of cancer treatment. 

Applications

Treatment against various cancers (e.g. breast, prostate, lung, brain, liver, and blood) as well as metastatic cancers. 

Advantages

• Could be the only singular treatment that effectively targets both the primary tumor as well as the metastatic tumor simultaneously.
• Potentially lower risk for adverse side effects 

Description

Replication-competent Adenovirus vectors are a highly favorable vehicle for cancer treatment given their ability to spread intra-tumorally and to script proteins that can have an additional therapeutic effect on systemic metastatic cancers.  Direct injection of the virus into human breast xenograft tumors grown in nude mice resulted in a significant inhibition of tumor growth causing complete tumor regressions in more than 85% of the animals. 

Patent Status: patent pending 

About The Inventor

Prem Seth, PhD is an Associate Research Professor for the Department of Medicine, at the Feinberg School of Medicine, Northwestern University.  He earned his PhD in Biochemistry at the University of Western Ontario, Canada and conducted post-doctoral work at the National Cancer Institute.  Dr. Seth is also a study section member of the American Cancer Society and the National Institutes of Health.  He is an Editorial Board Member of Cancer Gene Therapy and Cancer Biology and Therapy and has published more than 100 papers.

Please contact us for more information.